Cost-effective and noninvasive methods for in vivo imaging of amyloid deposition are needed to screen Alzheimer’s disease (AD). Although retinal amyloid is a possible diagnostic marker of AD, there are very few studies on in vivo retinal amyloid imaging.
Objective:
To examine the usefulness of in vivo imaging of retinal amyloid in AD patients.
Methods:
To examine amyloid deposition, 30 Japanese subjects (10 normal control (NC), 7 with mild cognitive impairment (MCI), and 13 with AD) underwent a complete ophthalmic examination, including fundus imaging by scanning laser ophthalmoscopy before and after oral curcumin intake.
Results:
Retinal amyloid deposition was greater in AD than in NC subjects (*p < 0.05) while MCI showed a slight but insignificant increase of retinal amyloid deposition relative to NC subjects. Retinal amyloid deposition was correlated with whole gray matter atrophy (r = 0.51, *p < 0.05) but not with the cognitive score of the Mini-Mental State Examination, nor with medial temporal lobe atrophy.
Conclusion:
The present noninvasive in vivo detection of retinal amyloid deposition is useful for screening AD patients.
HishikawaN, FukuiY, SatoK, KonoS, YamashitaT, OhtaY, DeguchiK, AbeK (2016) Characteristic features of cognitive, affective and daily living functions of late-elderly dementia. Geriatr Gerontol Int16, 458–465.
2.
DeTureMA, DicksonDW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener14, 32.
3.
IkonomovicMD, KlunkWE, AbrahamsonEE, MathisCA, PriceJC, TsopelasND, LoprestiBJ, ZiolkoS, BiW, PaljugWR, DebnathML, HopeCE, IsanskiBA, HamiltonRL, DeKoskyST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain131, 1630–1645.
4.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6, 131–144.
5.
LondonA, BenharI, SchwartzM (2013) The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol9, 44–53.
IwatsuboT (2010) Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and future. Alzheimers Dement6, 297–299.
8.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
9.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
10.
KatoS (1991) Development of the revised version of Hasegawa’s Dementia Scale (HDS-R). Jpn J Geriatr Psychiatry2, 1339–1347.
StarksteinSE, MaybergHS, PreziosiTJ, AndrezejewskiP, LeiguardaR, RobinsonRG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci4, 134–139.
13.
AbeK, YamashitaT, HishikawaN, OhtaY, DeguchiK, SatoK, MatsuzonoK, NakanoY, IkedaY, WakutaniY, TakaoY (2015) A new simple score (ABS) for assessing behavioral and psychological symptoms of dementia. J Neurol Sci350, 14–17.
14.
GalaskoD, BennettD, SanoM, ErnestoC, ThomasR, GrundmanM, FerrisS (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord11(Suppl 2), S33–S39.
15.
DumitrascuOM, LydenPD, TorbatiT, SheynJ, SherzaiA, SherzaiD, ShermanDS, RosenberryR, ChengS, JohnsonKO, CzeszynskiAD, VerdoonerS, FrautschyS, BlackKL, KoronyoY, Koronyo-HamaouiM (2020) al segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimers Dement (Amst)12, e12109.
16.
HirataY, MatsudaH, NemotoK, OhnishiT, HiraoK, YamashitaF, AsadaT, IwabuchiS, SamejimaH (2005) Voxel-based morphometry to discriminate early Alzheimer’s disease from controls. Neurosci Lett382, 269–274.
NingA, CuiJ, ToE, AsheKH, MatsubaraJ (2008) Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci49, 5136–5143.
Koronyo-HamaouiM, KoronyoY, LjubimovAV, MillerCA, KoMK, BlackKL, SchwartzM, FarkasDL (2011) Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage54(Suppl 1), S204–217.
21.
LeeS, JiangK, McIlmoyleB, ToE, XuQA, Hirsch-ReinshagenV, MackenzieIR, HsiungGR, EadieBD, SarunicMV, BegMF, CuiJZ, MatsubaraJA (2020) Amyloid beta immunoreactivity in the retinal ganglion cell layer of the Alzheimer’s eye. Front Neurosci14, 758.
22.
DoustarJ, RentsendorjA, TorbatiT, RegisGC, FuchsDT, SheynJ, MirzaeiN, GrahamSL, ShahPK, MastaliM, Van EykJE, BlackKL, GuptaVK, MirzaeiM, KoronyoY, Koronyo-HamaouiM (2020) Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer’s disease mouse models. Aging Cell19, e13246.
23.
SchultzN, BymanE, Netherlands Brain Bank, WennströmM (2020) Levels of retinal amyloid-beta correlate with levels of retinal IAPP and hippocampal amyloid-beta in neuropathologically evaluated individuals. J Alzheimers Dis73, 1201–1209.
24.
SchönC, HoffmannNA, OchsSM, BurgoldS, FilserS, SteinbachS, SeeligerMW, ArzbergerT, GoedertM, KretzschmarHA, SchmidtB, HermsJ (2012) Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One7, e53547.
25.
NguyenH, HaP, NguyenA, NguyenD, DoH, ThiQ, ThiM (2016) Curcumin as fluorescent probe for directly monitoring in vitro uptake of curcumin combined paclitaxel loaded PLA-TPGS nanoparticles. Adv Nat Sci Nanosci Nanotechnol7, 025001.
26.
YangF, LimGP, BegumAN, UbedaOJ, SimmonsMR, AmbegaokarSS, ChenPP, KayedR, GlabeCG, FrautschySA, ColeGM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem280, 5892–5901.
27.
OnoK, HasegawaK, NaikiH, YamadaM (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res75, 742–750.
DuLY, ChangLY, ArdilesAO, Tapia-RojasC, ArayaJ, InestrosaNC, PalaciosAG, AcostaML (2015) Alzheimer’s disease-related protein expression in the retina of Octodon degus. PLoS One10, e0135499.
30.
MaitiP, HallTC, PaladuguL, KolliN, LearmanC, RossignolJ, DunbarGL (2016) A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5x-familial Alzheimer’s disease mice. Histochem Cell Biol146, 609–625.
31.
ShiH, KoronyoY, RentsendorjA, RegisGC, SheynJ, FuchsDT, KramerovAA, LjubimovAV, DumitrascuOM, RodriguezAR, BarronE, HintonDR, BlackKL, MillerCA, MirzaeiN, Koronyo-HamaouiM (2020) Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathol139, 813–836.
32.
CarareRO, AldeaR, AgarwalN, BacskaiBJ, BechmanI, BocheD, BuG, BultersD, ClemensA, CountsSE, de LeonM, EidePK, FossatiS, GreenbergSM, HamelE, HawkesCA, Koronyo-HamaouiM, HainsworthAH, HoltzmanD, IharaM, JeffersonA, KalariaRN, KippsCM, KanninenKM, LeinonenV, McLaurinJ, MinersS, MalmT, NicollJAR, PiazzaF, PaulG, RichSM, SaitoS, ShihA, ScholtzovaH, SnyderH, SnyderP, ThormodssonFR, van VeluwSJ, WellerRO, WerringDJ, WilcockD, WilsonMR, ZlokovicBV, VermaA (2020) Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of amyloid-beta from the brain and retina with age and Alzheimer’s disease - Opportunities for therapy. Alzheimers Dement (Amst)12, e12053.
33.
WangX, LouN, EberhardtA, YangY, KuskP, XuQ, FörsteraB, PengS, ShiM, Ladrón-de-GuevaraA, DelleC, SigurdssonB, XavierALR, ErtürkA, LibbyRT, ChenL, ThraneAS, NedergaardM (2020) An ocular glymphatic clearance system removes beta-amyloid from the rodent eye. Sci Transl Med12, eaaw3210.
34.
SharafiSM, SylvestreJP, ChevrefilsC, SoucyJP, BeaulieuS, PascoalTA, ArbourJD, RhéaumeMA, RobillardA, ChayerC, Rosa-NetoP, MathotaarachchiSS, NasreddineZS, GauthierS, LesageF (2019) Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y)5, 610–617.
35.
BatemanRJ, XiongC, BenzingerTL, FaganAM, GoateA, FoxNC, MarcusDS, CairnsNJ, XieX, BlazeyTM, HoltzmanDM, SantacruzA, BucklesV, OliverA, MoulderK, AisenPS, GhettiB, KlunkWE, McDadeE, MartinsRN, MastersCL, MayeuxR, RingmanJM, RossorMN, SchofieldPR, SperlingRA, SallowayS, MorrisJC, for the Dominantly Inherited Alzheimer Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med367, 795–804.
36.
FoxNC, SchottJM (2004) Imaging cerebral atrophy: Normal ageing to Alzheimer’s disease. Lancet363, 392–394.
37.
GuptaV, GuptaVB, ChitranshiN, GangodaS, Vander WallR, AbbasiM, GolzanM, DheerY, ShahT, AvolioA, ChungR, MartinsR, GrahamS (2016) One protein, multiple pathologies: Multifaceted involvement of amyloid beta in neurodegenerative disorders of the brain and retina. Cell Mol Life Sci73, 4279–4297.
38.
PignataroA, MiddeiS (2017) Trans-synaptic spread of amyloid-beta in Alzheimer’s disease: Paths to beta-amyloidosis. Neural Plast2017, 5281829.
39.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ, Amyloid PET Study Group, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sanchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChetelatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. JAMA313, 1939–1949.
